Go to main contents Go to main menus

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

Research Articles

contents area

detail content area

Cilostazol‑based triple versus potent P2Y12 inhibitor‑based dual antiplatelet therapy in ...
  • Date2021-02-23 18:02
  • Update2021-02-23 18:02
  • CountersignatureDivision of Research Planning
  • Tel043-719-8033

Heart Vessels, 2020.35(9), 1181-1192, DOI: https://doi.org/10.1007/s00380-020-01598-w


Cilostazol‑based triple versus potent P2Y12 inhibitor‑based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention

Woohyeun Kim, Dong Oh Kang; Yoonjee Park; Jah Yeon Choi; Seung‑Young Roh; Jin Oh Na; Cheol Ung Choi; Eung Ju Kim; Chang Gyu Park; Hong Seog Seo; Se Yeon Choi; Jae Kyeong Byun; Jinah Cha; Dong Joo Oh; Myung Ho Jeong;Seung‑Woon Rha; Byoung Geol Choi; Won Young Jang


Abstract

    Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients. We compared the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAT) with potent P2Y12 inhibitor-based DAPT in Korean patients. A total of 4152 AMI patients who underwent percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry were analyzed retrospectively. Patients were divided into two groups: the TAT group (aspirin + clopidogrel + cilostazol, n = 3161) and the potent DAPT group (aspirin + potent P2Y12 inhibitors [ticagrelor or prasugrel], n = 991). Major clinical outcomes at 30 days and 2 years were compared between the two groups using propensity score matching (PSM) analysis. After PSM (869 pairs), there were no significant differences between the two groups in the incidence of total death, cardiac death, myocardial infarction (MI), target vessel revascularization, stent thrombosis, and stroke at 30 days and 2 years. However, the Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding rates were significantly lower in the TAT group compared with the potent DAPT group at 2 years (6.4% vs. 3.6%, p = 0.006). In Korean AMI patients undergoing PCI, TAT with cilostazol was associated with lower bleeding than the potent P2Y12 inhibitor-based DAPT without increased ischemic risk. These results could provide a rationale for the use of TAT in East Asian AMI patients.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.


This public work may be used under the terms of the public interest source This public work may be used under the terms of the public interest source
TOP